All In Biotech

Drug Trial Radar · NCT07871097

Acute Treatment of Vestibular Migraine by Rimegepant

Efficacy of Rimegepant in the Treatment of Acute Vestibular Migraine -- Multicenter, Prospective, Cross-design, Randomized, Placebo-controlled Study

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Dec 1, 2025

Primary completion

Nov 30, 2027

Study completion Dec 1, 2027

Sponsor

Lead sponsor
Wensheng QuAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Wuhan No.1 Hospital; Wuhan Puren Hospital; Xiangyang Central Hospital; Xinyang Central Hospital
First posted
Oct 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate whether rimegepant improves acute vestibular symptoms and accompanying discomforts in patients with vestibular migraine.

Conditions

  • Vestibular Migraine

Interventions

  • First dose rimegepant, second dose placeboDrug

    First dose rimegepant, second dose placebo

  • First dose placebo, second dose rimegepantDrug

    First dose placebo, second dose rimegepant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Vertigo symptom relief rateTime frame: 2 hours after medication

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tongji Hospital

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.